This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demaria, S. Articles by Symmans, W. F. Search for Related Content PubMed PubMed Citation Articles by Demaria, S. Articles by Symmans, W. F.

Development of Tumor-infiltrating Lymphocytes in Breast Cancer after Neoadjuvant Paclitaxel Chemotherapy¹

Departments of Pathology [S. D., H. T. Y., W. F. S.], Medicine [M. D. V., R. O., F. M.], Surgery [R. L. S.], Radiation Oncology [S. C. F.], and Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016

	ABSTRACT

Top ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Purpose: Neoadjuvant chemotherapy for breast cancer creates new possibilities for the analysis of biological factors in the tumor and/or host, which may play a role in the response to treatment. In this study we analyzed whether changes in local antitumor immunity take place after neoadjuvant paclitaxel therapy and if they correlate with response to treatment.

Experimental Design: Neoadjuvant chemotherapy (paclitaxel, 200 mg/m2 q2w, 4 treatments) was followed by definitive surgical management. Histological sections from the pre- and post-treatment surgical specimens of 25 patients were analyzed for the extent of lymphocytic infiltration and presence of tumor infiltrating lymphocytes (TILs). The cumulative apoptotic response in the tumor after the first dose of paclitaxel was also studied in 10 of 25 patients.

Results: Pretreatment lymphocytic infiltrate in the tumor was minimal in the majority of patients and showed no relationship with clinical response. In the patients without TILs before treatment, development of TILs after treatment was noted in 0/3 (0%) patients with stable disease, 3/12 (25%) patients with clinical partial response, and 4/6 (67%) patients with clinical complete response and pathological residual disease. These correlated with the tumor cell apoptotic response to the first dose of paclitaxel.

Conclusions: These results suggest that development of TILs after treatment correlates with clinical response to neoadjuvant paclitaxel therapy. The possible mechanism(s) whereby neoadjuvant chemotherapy may lead to induction of antitumor T cells is discussed. Immunological processes may influence the response of breast cancer patients to neoadjuvant treatment.

	INTRODUCTION

Top ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Many patients with breast cancer are currently suitable candidates for neoadjuvant (preoperative, induction) chemotherapy to facilitate the complete surgical excision of the tumor and to initiate early systemic treatment of distant micrometastases (reviewed in Ref. 1 ). This approach provides an opportunity to assess tumor sensitivity/resistance to the preoperative regimen by measuring the residual disease in the resection specimen obtained at surgery. Evidence is emerging that a good pathological response (i.e., complete or nearly complete destruction of the tumor in the surgical specimen) after neoadjuvant chemotherapy is a strong predictor for survival (2, 3, 4) . Indeed, breast cancer patients with a complete pathological response have an excellent DFS and overall survival, but they represent only a minority of the patients treated with chemotherapy alone (3, 4, 5) .

Induction of tumor antigen-specific CTLs⁴ can be efficacious in the prevention and treatment of experimental tumors (reviewed in Ref. 6 ). However, poor immunogenicity of tumor cells often prevents development of an effective antitumor immune response. Recent data strongly suggest that presentation of tumor-derived antigens by DCs is a necessary step in the induction of an immune response to the tumor (reviewed in Ref. 7 ). DCs can acquire antigens from apoptotic cells and stimulate antigen-specific MHC class I-restricted CTLs (8) . Apoptotic death is a critical requirement for antigen presentation on MHC class I molecules of DCs, because antigens from necrotic cells cannot enter this pathway (8) . Importantly, a high ratio of apoptotic cells:DCs can also induce DC maturation, thus enhancing DC ability to efficiently present antigens derived from the apoptotic cells to T cells (9) .

The chemotherapeutic agent paclitaxel induces apoptosis in susceptible cells and is effective against breast cancer. In experimental murine breast cancer models, the degree of paclitaxel-induced apoptosis correlates with its antitumor effect (10) . Recently, we have shown that the apoptotic response to the first dose of paclitaxel administered as neoadjuvant chemotherapy to breast cancer patients can be measured in the tumor from serial FNAs (11) . The apoptotic response appeared to predict the amount of cancer reduction from the treatment (11) .

Several studies in breast and other cancers support the notion that tumor infiltration by lymphocytes indicates an antitumor cellular immune response (12, 13, 14, 15, 16) . In addition, the degree of lymphocytic infiltration and, especially, the presence of lymphocytes within tumor cell nests has been shown to correlate with a better prognosis in many tumor types (17, 18, 19, 20, 21, 22) . Therefore, TILs indicate a cellular antitumor immune response that may contribute to control growth and spread of some tumors.

The study of tumor molecular characteristics that play a role in response to neoadjuvant therapy is an area of active investigation (reviewed in Ref. 1 ). Histological changes after neoadjuvant chemotherapy of breast cancer have been reported previously (23, 24, 25, 26) . However, the effects of treatment on tumor/host interactions have not been assessed. To test whether increased apoptosis in the tumor promotes an antitumor immune response, we evaluated the extent of lymphocytic infiltration and presence of TILs in histological sections from pre- and post-treatment surgical specimens from breast cancer patients who received neoadjuvant paclitaxel chemotherapy. Our data suggest that antitumor T-cell responses are triggered in the host when chemotherapy-mediated killing of the cancer cells in the primary tumor is efficient. Elicited tumor-specific CTLs may then contribute to eliminate cancer cells that have survived neoadjuvant treatment.

	PATIENTS AND METHODS

Top ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES

 
A neoadjuvant paclitaxel protocol was offered to women with primary breast cancer if the tumor was T2 or greater and there was no evidence of systemic metastatic disease. Four pretreatment core biopsies (14-gauge) were obtained from different parts of the tumor mass for tissue diagnosis and immunohistochemical assays of selected biomarkers. After obtaining informed consent for treatment from the patients, paclitaxel (200 mg/m²) was administered for 3 h as an i.v. infusion and was given every 2 weeks for a total of four cycles. Surgery was usually performed 2–3 weeks after the last dose of paclitaxel. The post-treatment surgical specimen was thoroughly examined and the tumor bed extensively sampled. Postoperative chemotherapy (doxorubicin and cyclophosphamide) and radiation therapy were administered as adjuvant treatment. Tamoxifen was subsequently added for patients who had tumors positive for estrogen and/or progesterone receptors.

Clinical response to neoadjuvant paclitaxel chemotherapy was determined as reported previously (11 , 27) . Women who opted for neoadjuvant paclitaxel chemotherapy were also offered participation in a clinical trial using serial FNAs to assess apoptotic response to the first dose of paclitaxel as reported previously (11) . Ten of the 25 patients consented to participate. Briefly, the primary tumor was sampled by FNA before the core biopsy (before chemotherapy) to obtain a baseline value and at 24, 48, 72, and 96 h after the first paclitaxel infusion. H&E-stained cytology smears prepared from this material were analyzed microscopically, and the number of apoptotic cells in 1000 cancer cells was recorded as percentage (index). The apoptotic index at each time point was divided by the pretreatment index and expressed as a ratio to correct for variability in baseline indices from different tumors. The cumulative apoptotic response for the first 96 h of treatment was then calculated as sum of ratios. For more details see Symmans et al. (11) .

To evaluate the extent of lymphocytic infiltration in the primary tumor and the presence of TILs, H&E-stained histological sections from the pretreatment biopsy and post-treatment surgical specimens from 25 patient breast cancers were analyzed. A grading system for semiquantitative scoring of lymphocytic infiltration in breast cancer has been established by Black et al. (17) . In this system, grade 0 corresponds to absence of lymphocytes and grades 1–4 to increasing degree of lymphocytic infiltration from a few scattered cells (grade 1) to marked infiltrate that mimics a lymphoid organ (grade 4). Two components of lymphocytic infiltration have been recognized: lymphocytes scattered in the stroma surrounding the tumor are defined as tumor-associated lymphocytes, whereas lymphocytes present within tumor cell nests are defined as TILs (reviewed in Ref. 12 ). Recent studies suggest that only TILs may correlate with an efficacious antitumor response (21 , 22) . In Black’s scoring system tumor-associated lymphocytes and TILs are not clearly defined. Therefore, a modification of Black’s scoring system was used in the present study. First, to improve interobserver reproducibility, intermediate degrees of lymphocytic infiltrate were grouped into a single category: the lymphocytic infiltrate was scored as absent (grade 0), minimal (grade 1), moderate (grades 2 and 3), and brisk (grade 4; Fig. 1 ). Second, presence of TILs (lymphocytes infiltrating within carcinoma cell nests) was assessed in at least 10 fields at high power magnification (x 400). TILs were always absent when the infiltrate was minimal and present in association with brisk infiltrate. However, in some cases with a moderate infiltrate, lymphocytes were confined to the stroma with no or only focal presence within tumor cell nests. These cases were considered to be negative for TILs. Grading of TILs (e.g., number of lymphocytes relative to tumor cells and/or area) was not possible given the limited number of cases available for evaluation and the low frequency of this finding.

View larger version (88K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. TILs within the residual breast cancer after neoadjuvant chemotherapy. Histological sections from the pretreatment biopsy (Pre) and post-treatment surgical specimens (Post) were stained with H&E or immunohistochemically stained for CD3, CD8, or TIA-1. A, a patient with CPR showing minimal lymphocytic infiltrate without TILs pretreatment and development of TILs after treatment accompanied by an increase of lymphocytic infiltration to moderate. Rare T cells (CD3+) are scattered in the stroma in the pretreatment specimen, whereas after treatment they are infiltrating tumor cell nests (x400). B, a patient with CCR/PRD showing minimal pretreatment and brisk post-treatment lymphocytic infiltrate with development of TILs. T cells (CD3+) are seen infiltrating and disrupting residual tumor cell nests (x400). CD8+ and TIA-1+ TILs interacting with the tumor cells are seen after treatment (x1000).

	RESULTS

Top ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES

 
H&E-stained histological sections from the pretreatment biopsy and post-treatment surgical specimens of 25 patients (Table 1) treated between May 1997 and October 1999 were evaluated for the morphological equivalent of a cellular antitumor immune response. At surgery, 5 patients had SD (<50% diameter reduction), 13 had CPR, 6 had CCR/PRD, and 1 had PCR. Clinical results and correlates with apoptotic response have been reported previously (11 , 27) . No significant change in morphological appearance of the tumors was noted after treatment. Necrosis was seen pre- and post-treatment in a few very large tumors (7–11 cm) suggesting that its presence was related to tumor size more than treatment.

After treatment, TILs were identified in 7 of the 21 patients with residual tumor that had no TILs before treatment (Fig. 1) . An increase in the degree of lymphocytic infiltration to moderate or brisk always accompanied the development of TILs, whereas there was no increase in the degree of lymphocytic infiltration without TILs. Development of TILs was not seen in patients with SD but was noted in 25% of patients with CPR and 67% of patients with CCR/PRD (Table 3) . Interestingly, when the patients with CCR/PRD were additionally stratified based on the amount of residual cancer determined pathologically, the 2 patients that did not develop TILs had the largest residual tumor and 1 had lymph node metastases. Therefore, there is an apparent relationship between response to neoadjuvant treatment and development of an antitumor cellular response that can be appreciated by histopathology. Immunohistochemical staining showed that the majority of TILs were T cells and that CD8+ CTL were present among cancer cells (Fig. 1B) . Moreover, many TILs containing TIA-1-positive cytotoxic granules were seen interacting with residual cancer cells (Fig. 1B) . This suggests the possibility that at least some of the cancer cells surviving chemotherapy may be killed by antitumor CTLs.

Data from 10 patients were available on the apoptotic response in the tumor 96 h after the first dose of paclitaxel. As reported previously by Symmans et al. (11) the apoptotic response to paclitaxel strongly correlated with tumor reduction. There was a tendency for those patients who had a significantly strong apoptotic response after chemotherapy to develop TILs in the residual tumor (Fig. 2) . In contrast, no increase in TILs was seen in any of the patients with poor or no response to chemotherapy. Because the apoptotic response was measured shortly after administration of the first dose of paclitaxel, it is unlikely that killing of tumor cells by TILs could have influenced the amount of observed apoptosis. Therefore, these data suggest that the extent of cell death induced in a tumor by paclitaxel chemotherapy may contribute to the development of an antitumor immune response.

View larger version (13K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Relationship between apoptotic response of tumor cells to neoadjuvant chemotherapy and development of TILs. The patients studied generally showed an apoptotic response over the first 4 days after the first dose of paclitaxel, which was usually complete by day 4. The apoptotic index at each time point was divided by the pretreatment baseline index (0 h) and expressed as a ratio. The cumulative apoptotic response was calculated as sum of ratios (for more details see Ref. 11 ). , cases showing no change in the lymphocytic infiltrate after treatment; •, cases showing development or increase in the extent of TILs after treatment; and , 1 case with no residual tumor (only scar tissue) after treatment. The cumulative apoptotic response after the first dose of paclitaxel shows a correlation with development of TILs.

	DISCUSSION

Top ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES

In the four cases with presence of TILs before treatment, the response to neoadjuvant chemotherapy was poor: two patients had SD and two CPR. This could suggest that patients with pretreatment TILs may be less likely to respond to paclitaxel. However, three of the four cases were ductal carcinomas with medullary features, a subtype always associated with the presence of TILs but with other distinct cytological and histological characteristics. Therefore, it is possible that this tumor type has an "intrinsic" resistance to the action of paclitaxel, which is unrelated to the presence of TILs. Indeed, the observed correlation between tumor reduction and apoptotic response of tumor cells to the first dose of paclitaxel (11) suggests that the intrinsic sensitivity of cancer cells to paclitaxel is a primary determinant of response. If the tumor is sensitive to the chemotherapy, the accumulation of apoptotic cancer cells may trigger immune mechanisms that contribute to the elimination of surviving cancer cells. Unfortunately, chemotherapy alone leads to accumulation of apoptotic cancer cells in only a fraction of treated patients (11) . Treatments capable of inducing sufficient accumulation of apoptotic tumor cells in a larger proportion of patients may be also more efficient at triggering antitumor immune responses. One promising approach is the use of concomitant local radiation and chemotherapy as neoadjuvant treatment for locally advanced breast cancer (30, 31, 32) .

Recent reports suggest that the accumulation of apoptotic tumor cells above a certain threshold can trigger DC uptake and presentation of tumor antigens and ultimately result in the induction of antitumor T lymphocytes (9 , 33) . Thus, induction of apoptosis of tumor cells after paclitaxel treatment may also enhance tumor immunogenicity by providing tumor antigens for presentation by DC to T lymphocytes. In addition, paclitaxel may be distinctive among chemotherapeutic agents in its ability to stimulate production by monocytes and cancer cells of cytokines such as interleukin 1ß, a potent inducer of DC maturation (34 , 35) . The presence of cytolytic effector cells among residual tumor cells after treatment (Fig. 1B) does support a hypothesis that activation of a cytolytic T-cell response contributes to additional elimination of cancer cells. It is intriguing to consider whether a longer interval between completion of neoadjuvant treatment and subsequent surgery would convert some patients with pathological minimal residual disease and TILs into a PCR.

A limitation of the present study is that specificity and functional capacity of TILs could not be tested with the available material. Development of preclinical models is required to unequivocally test the hypothesis that induction of apoptosis of cancer cells by neoadjuvant therapy can enhance tumor immunogenicity and induce effective antitumor immune responses. We are currently working to develop such models. In addition, long-term follow-up of the patients should provide information about whether the development of TILs after chemotherapy is associated with an improved DFS. Such correlation would add support to the hypothesis that the lymphocytic infiltrate represents a correlate of a protective antitumor immune response (21 , 22) .

Recent data in an animal model strongly suggest that efficient killing of cancer cells by local radiation therapy of the primary tumor can provide tumor antigens for presentation by DC and trigger an immune response capable of controlling distant metastases when combined with immunomodulators to enhance DC function (36) . The data presented here suggest that chemotherapy-mediated killing of breast cancer cells, when efficient, may also activate antitumor T cells in some patients. If proven in larger studies, that would support the selection of neoadjuvant protocols with strong local antitumor effect (e.g., chemotherapy combined with local radiation; Refs. 30, 31, 32 ) as initial treatment of breast cancer. In addition, because DC function is depressed in many breast cancer patients (37) , concomitant use of cytokines enhancing DC function may be required to induce an effective and long-lasting antitumor immunity that would improve the survival of these patients. Interestingly, a recently reported clinical study indicates an encouraging improvement in DFS and overall survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy combined with granulocyte-macrophage colony stimulating factor, which can enhance DC function, (38 , 39) . We are beginning new clinical protocols designed to augment the local pathological response to chemotherapy by including radiation therapy in the neoadjuvant treatment. An important part of this work will be studying the molecular and immunological events that accompany the response to treatment.

	ACKNOWLEDGMENTS

 
We thank Luis Chiriboga for expert assistance with immunohistochemistry and the patients who participated in the study.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by NIH Grant 5K12 CA01713, a General Clinical Research Center Grant from the NIH, NCRR (M01-RR00096) awarded to New York University School of Medicine, and American Cancer Society Grant CRTG-99-01-CCE. Presented in part at the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1–5, 2000.

² To whom requests for reprints should be addressed, at Department of Pathology, MSB-121, New York University School of Medicine, 550 First Avenue, New York, NY 10016. Phone: (212) 263-6442; Fax: (212) 263-8179; E-mail: sandra{at}phri.nyu.edu

³ Present address: Department of Pathology, Box 85, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.

⁴ The abbreviations used are: CTL, cytolytic T cell; DC, dendritic cell; FNA, fine needle aspiration biopsy; TIL, tumor infiltrating lymphocyte; SD, stable disease; CPR, clinical partial response; DFS, disease-free survival; CCR, clinical complete response; PRD, pathological residual disease; PCR, pathological complete response.

Received 2/ 2/01; revised 7/11/01; accepted 7/12/01.

	REFERENCES

Top ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Bhalla K., Harris W. B. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin. Oncol., 25 (Suppl 3): 19-24, 1998.[Medline]
2. Feldman L. D., Hortobagyi G. N., Buzdar A. U., Ames F. C., Blumenschein G. R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res., 46: 2578-2581, 1986.[Abstract/Free Full Text]
3. Bonadonna G., Valgussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., Zambetti M. Primary chemotherapy in operable breast cancer. Eight-year experience at the Milan Cancer Institute. J. Clin. Oncol., 16: 93-100, 1998.[Abstract/Free Full Text]
4. Kuerer H. M., Newman L. A., Smith T. L., Ames F. C., Hunt K. K., Dhingra K., Theriault R. L., Singh G., Binkley S. M., Sneige N., Bucholtz T. A., Ross M. I., McNeese M. D., Buzdar A. U., Hortobagyi G. N., Singletary S. E. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol., 17: 460-469, 1999.[Abstract/Free Full Text]
5. Fisher B., Bryant J., Wolmark N., Mamaunas E., Brown A., Fisher E. R., Wickerham D. L., Begovic M., DeCillis A., Robidoux A., Margolese R. G., Cruz A. B. J., Hoehn J. L., Lees A. W., Dimitrov N. V., Bear H. D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol., 16: 2672-2685, 1998.[Abstract]
6. Melief C. J. M. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res., 58: 143-175, 1992.[Medline]
7. Luykx-de Bakker S. A., de Gruijl T. D., Scheper R. J., Wagstaff J., Pinedo H. M. Dendritic cells: a novel therapeutic modality. Ann. Oncol., 10: 21-27, 1999.[Free Full Text]
8. Albert M. L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (Lond.), 392: 86-89, 1998.[CrossRef][Medline]
9. Rovere P., Vallinoto C., Bondanza A., Crosti M. C., Rescigno M., Ricciardi-Castagnoli P., Rugarli C., Manfredi A. A. Cutting edge: bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol., 161: 4467-4471, 1998.[Abstract/Free Full Text]
10. Milross C. G., Mason K. A., Hunter N. R., Chung W-K., Peters L. J., Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst., 88: 1308-1314, 1996.[Abstract/Free Full Text]
11. Symmans W. F., Volm M. D., Shapiro R. L., Perkins A. B., Kim A. Y., Demaria S., Yee H. T., McMullen H., Oratz R., Klein P., Formenti S. C., Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin. Cancer Res., 6: 4610-4617, 2000.[Abstract/Free Full Text]
12. Hadden J. W. The immunology and immunotherapy of breast cancer: an update. Int. J. Immunopharmacol., 21: 79-101, 1999.[CrossRef][Medline]
13. Rabinowich H., Cohen R., Bruderman I., Steiner Z., Klajman A. Functional analysis of mononuclear cell infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res., 47: 173-177, 1987.[Abstract/Free Full Text]
14. Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol., 142: 3714-3725, 1989.[Abstract]
15. Baxevanis C. N., Dedoussis G. V. Z., Papadopoulos N. G., Missitzis I., Stathopoulos G. O., Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer (Phila.), 74: 1275-1282, 1994.[CrossRef][Medline]
16. Toso J. F., Oei C., Oshidari F., Tartaglia J., Paoletti E., Lyerly H. K., Talib S., Weinhold K. J. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res., 56: 16-20, 1996.[Abstract/Free Full Text]
17. Black M. M., Speer F. D., Opler S. R. Structural representations of tumor host relationship in mammary carcinoma: biologic and prognostic significance. Am. J. Clin. Pathol., 26: 250-265, 1956.
18. Shimokawara I., Imamura M., Yamanaka N., Ishii Y., Kikuchi K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer (Phila.), 49: 1456-1464, 1982.[CrossRef][Medline]
19. Aaltomaa S., Lipponen P., Eskelinen M., Kosma V. M., Marin S., Alhava E., Syrjanen K. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur. J. Cancer, 28A: 859-864, 1992.[CrossRef]
20. Di Giorgio A., Mingazzini P., Sammartino P., Canavese A., Arnone P., Scarpini M. Host defense and survival in patients with lung carcinoma. Cancer (Phila.), 89: 2038-2045, 2000.[CrossRef][Medline]
21. Clemente C. G., Mihm M. C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (Phila.), 77: 1303-1310, 1996.[CrossRef][Medline]
22. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res., 58: 3491-3494, 1998.[Abstract/Free Full Text]
23. Kennedy S., Merino M. J., Swain S. M., Lippman M. E. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum. Pathol., 21: 192-198, 1990.[CrossRef][Medline]
24. Frierson H. F., Fechner R. E. Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. Am. J. Clin. Pathol., 102: 154-157, 1994.[Medline]
25. Rasbridge S. A., Gillett C. E., Seymour A. M., Patel K., Richards M. A., Rubens R. D., Millis R. R. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br. J. Cancer, 70: 335-341, 1994.[Medline]
26. Honkoop A. H., Pinedo H. M., De Jong J. S., Verheul H. M. W., Linn S. C., Hoekman K., Wagstaff J., Van Diest P. J. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am. J. Clin. Pathol., 107: 211-218, 1997.[Medline]
27. Volm M. D., Formenti S. C., Symmans W. F., Downey A., Muggia F. Neo-adjuvant paclitaxel for locally advanced breast cancer: preliminary results. Proc. Am. Soc. Clin. Oncol., 17: 695 1998.
28. Ridolfi R., Rosen P., Port A., Kinne D., Mike V. Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer (Phila.), 40: 1365-1385, 1977.[CrossRef][Medline]
29. Yakirevich E., Izhak Ben O., Rennert G., Kovacs Z. G., Resnick M. B. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod. Pathol., 12: 1050-1056, 1999.[Medline]
30. Formenti S. C., Dunnington G., Uzieli B., Lenz H., Keren-Rosenberg S., Silberman H., Spicer D., Denk M., Leichman G., Groshen S., Watkins K., Muggia F., Florentine B., Press M., Danenberg K., Danenberg P. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated pre-operatively with continuous infusion 5-fluorouracil and radiation therapy. Int. J. Radiation Oncol. Biol. Phys., 39: 1059-1068, 1997.[CrossRef][Medline]
31. Formenti S. C., Symmans W. F., Volm M., Skinner K., Cohen D., Spicer D., Danenberg P. Concurrent paclitaxel and radiation therapy for breast cancer. Semin. Radiat. Oncol., 9 (2 Suppl 1): 34-42, 1999.[Medline]
32. Aryus B., Audretsch W., Gogolin F., Gripp S., Konigshausen T., Lammering G., Rohn R., Hartmann K. A. Remission rates following preoperative chemotherapy and radiation therapy in patients with breast cancer. Strahlenther Onkol., 176: 411-415, 2000.[CrossRef][Medline]
33. Ronchetti A., Rovere P., Iezzi G., Galati G., Heltai S., Protti M. P., Garancini M. P., Manfredi A. A., Rugarli C., Bellone M. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol., 163: 130-136, 1999.[Abstract/Free Full Text]
34. Byrd C. A., Bornmann W., Erdjument-Brimage H., Tempst P., Pavletich N., Rosen N., Nathan C., Ding A. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. USA, 96: 5645-5650, 1999.[Abstract/Free Full Text]
35. White C. M., Martin B. K., Lee L-F., Haskill J. S., Ting J. P-Y. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes. T lymphocytes, and breast cancer cells. Cancer Immunol. Immunother., 46: 104-112, 1998.[CrossRef][Medline]
36. Chakravarty P. K., Alfieri A., Thomas E. K., Beri V., Tanaka K. E., Vikram B., Guha C. Flt3-Ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res., 59: 6028-6032, 1999.[Abstract/Free Full Text]
37. Gabrilovich D. I., Corak J., Ciernik I. F., Kavanangh D., Carbone D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.[Abstract]
38. Honkoop A., Luykx-de Bakker S., Hoekman K., Meyer S., Meyer O., van Groeningen C., van Diest P., Boven E., van der Wall E., Giaccone G., Wagstaff J., Pinedo H. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist, 4: 106-111, 1999.[Abstract/Free Full Text]
39. Luykx-de Bakker S. A., Verheul H. M., de Gruijl T. D., Pinedo H. M. Prolonged neoadjuvant treatment in locally advanced tumors: a novel concept based on biological considerations. Ann. Oncol., 10: 155-160, 1999.[Abstract/Free Full Text]

This article has been cited by other articles:

				E. A. Hirschowitz and J. R. Yannelli Immunotherapy for Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 224 - 232. [Abstract] [Full Text] [PDF]

				J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G. G. Steger, A. Makhson, S. Tjulandin, H. Ludwig, M. Verrill, et al. Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer J. Clin. Oncol., February 1, 2009; 27(4): 526 - 534. [Abstract] [Full Text] [PDF]

				L. de la Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. Codes-Manuel de Villena Cancer and Immune Response: Old and New Evidence for Future Challenges Oncologist, December 1, 2008; 13(12): 1246 - 1254. [Abstract] [Full Text] [PDF]

				S. C. Formenti and S. Demaria Effects of Chemoradiation on Tumor-Host Interactions: The Immunologic Side J. Clin. Oncol., March 20, 2008; 26(9): 1562 - 1563. [Full Text] [PDF]

				A. E. M. Dirkx, M. G. A. oude Egbrink, K. Castermans, D. W. J. van der Schaft, V. L. J. L. Thijssen, R. P. M. Dings, L. Kwee, K. H. Mayo, J. Wagstaff, J. C. A. B. ter Steege, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors FASEB J, April 1, 2006; 20(6): 621 - 630. [Abstract] [Full Text] [PDF]

				L. A. Emens and E. M. Jaffee Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy Cancer Res., September 15, 2005; 65(18): 8059 - 8064. [Abstract] [Full Text] [PDF]

				A. S. Fairey, K. S. Courneya, C. J. Field, G. J. Bell, L. W. Jones, and J. R. Mackey Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors J Appl Physiol, April 1, 2005; 98(4): 1534 - 1540. [Abstract] [Full Text] [PDF]

				L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]

				S. Demaria, F. R. Santori, B. Ng, L. Liebes, S. C. Formenti, and S. Vukmanovic Select forms of tumor cell apoptosis induce dendritic cell maturation J. Leukoc. Biol., March 1, 2005; 77(3): 361 - 368. [Abstract] [Full Text] [PDF]

				W. E. Carson III, C. L. Shapiro, T. R. Crespin, L. M. Thornton, and B. L. Andersen Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment Clin. Cancer Res., May 15, 2004; 10(10): 3401 - 3409. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demaria, S. Articles by Symmans, W. F. Search for Related Content PubMed PubMed Citation Articles by Demaria, S. Articles by Symmans, W. F.